children
malign
hematopoiet
stem
cell
transplant
hsct
recipi
increas
risk
healthcareassoci
infect
hai
due
underli
diagnos
well
receipt
immunosuppress
medic
part
treatment
addit
frequent
visit
healthcar
set
increas
risk
exposur
resist
organ
thu
adher
infect
control
prevent
measur
recommend
hospit
children
essenti
addit
intervent
reduc
inher
risk
morbid
associ
hai
warrant
special
popul
variou
factor
contribut
increas
suscept
infect
pediatr
hematologyoncolog
pho
hsct
patient
promin
disrupt
cutan
mucos
barrier
oral
gastrointestin
etc
microbi
gastrointestin
transloc
defect
cellmedi
immun
insuffici
quantiti
inadequ
function
phagocyt
goal
infect
control
prevent
popul
base
mitig
risk
inher
underli
malign
associ
treatment
ie
chemotherapi
variou
factor
contribut
increas
suscept
infect
pediatr
hematologyoncolog
pho
hsct
patient
promin
disrupt
cutan
mucos
barrier
oral
gastrointestin
etc
microbi
gastrointestin
transloc
defect
cellmedi
immun
insuffici
quantiti
inadequ
function
phagocyt
goal
infect
control
prevent
popul
base
mitig
risk
inher
underli
malign
associ
treatment
ie
chemotherapi
radiat
chapter
discuss
infect
control
prevent
measur
specif
patient
hematolog
malign
well
hsct
recipi
hand
hygien
standard
precaut
care
pho
hsct
patient
key
compon
reduc
risk
infect
addit
isol
precaut
may
also
undertaken
depend
pathogen
isol
andor
symptom
patient
experienc
eg
contact
precaut
would
appropri
patient
experienc
diarrhea
inform
gener
infect
prevent
measur
found
chap
minim
injuri
mucos
surfac
decreas
heavi
colon
skin
reduc
likelihood
microbi
invas
site
thu
import
meticul
skin
care
daili
inspect
pho
hsct
patient
paramount
provid
opportun
identifi
area
inflamm
breakdown
earli
skin
inspect
done
routin
special
attent
highrisk
area
like
intravascular
cathet
insert
site
perineum
rectal
thermomet
digit
rectal
examin
suppositori
avoid
prevent
mucos
breakdown
part
effort
reduc
colon
cutan
surfac
daili
chlorhexidin
bath
shown
reduc
hai
transmiss
multidrugresist
organ
mdro
oncolog
patient
chlorhexidin
glucon
chg
cation
bisbiguanid
serv
topic
antisept
chg
bind
neg
charg
bacteri
cell
wall
protein
alter
bacteri
cell
wall
equilibrium
help
reduc
bacteri
colon
skin
educ
patient
famili
staff
import
practic
key
complianc
prevent
strategi
made
prioriti
mani
expert
recommend
complet
periodont
examin
perform
prior
initi
chemotherapi
reevalu
throughout
treatment
cours
complet
oral
mucos
consid
acut
inflamm
andor
ulcer
oraloropharyng
mucu
membran
common
advers
effect
chemotherapeut
agent
caus
oral
paindiscomfort
well
difficulti
eat
swallow
speech
mucos
commonli
caus
chemotherapeut
agent
prevent
dna
synthesi
methotrex
cytarabin
particularli
hsct
recipi
oral
rins
normal
salin
chgcontain
product
recommend
time
per
day
prevent
oral
mucos
patient
pain
mucos
might
compli
oral
care
regimen
howev
put
increas
risk
infect
oral
flora
bacteremia
due
viridan
streptococci
mouth
rins
contain
alcohol
avoid
aggrav
mucos
neutropen
patient
also
instruct
brush
teeth
care
order
prevent
gingiv
injuri
regular
soft
toothbrush
electr
brush
use
minim
trauma
elect
dental
procedur
ideal
perform
prior
start
chemotherapi
discuss
primari
medic
team
absolut
neutrophil
count
platelet
count
stage
treatment
consid
perform
dental
procedur
vulner
popul
presenc
central
venou
cathet
cvc
popul
put
risk
central
lineassoci
bloodstream
infect
clabsi
relat
complic
clabsi
commonli
report
hai
pediatr
seri
among
pediatr
hai
report
nation
healthcar
surveil
network
nhsn
oncolog
unit
streptococcu
viridan
klebsiella
pneumoniaeoxytoca
two
common
pathogen
studi
nhsn
report
antibiot
resist
note
high
oncolog
unit
includ
ampicillin
andor
vancomycin
resist
enterococcu
faecium
fluoroquinolon
resist
escherichia
coli
although
less
enterobacteriacea
report
carbapenem
resist
emerg
organ
popul
signific
concern
among
candida
infect
popul
fluconazol
resist
among
nonc
albican
nonc
parapsilosi
isol
wherea
fluconazol
resist
c
albican
c
parapsilosi
mucos
barrier
injuri
mbi
associ
laboratoryconfirm
bloodstream
infect
mbilcbi
gain
attent
recent
year
clabsi
relat
primarili
mucos
barrier
injuri
ie
mucos
due
direct
presenc
cvc
per
se
nhsn
definit
posit
blood
cultur
would
qualifi
mbilcbi
result
one
group
select
commens
organ
oral
caviti
gastrointestin
tract
occur
presenc
sign
symptom
consist
mucos
barrier
injuri
mbi
pho
hsct
patient
elig
organ
mbilcbi
includ
candida
speci
enterococcu
enterobacteriacea
viridan
group
streptococci
streptococcu
speci
anaerob
specif
guidelin
central
line
insert
mainten
bundl
propos
center
diseas
control
prevent
cdc
infecti
diseas
societi
america
idsa
reduc
clabsi
rate
healthcar
cost
sever
studi
demonstr
multifacet
approach
reduc
clabsi
rate
popul
includ
standard
cvc
insert
practic
mainten
bundl
track
cvc
infect
use
standard
definit
use
dedic
nurs
staff
cvc
champion
specif
train
cvc
mainten
track
conjunct
infect
control
method
includ
oral
hand
hygien
optim
nursepati
ratio
etc
clabsi
discuss
greater
detail
chap
american
societi
blood
marrow
transplant
recommend
low
microbi
diet
hsct
recipi
littl
evid
howev
suggest
help
pho
patient
routin
safeti
handl
prepar
food
practic
patient
parent
gener
eat
unpasteur
milk
chees
undercook
meat
raw
fruit
veget
discourag
period
neutropenia
reduc
incid
infect
need
minim
risk
infect
howev
balanc
nutrit
need
qualiti
life
patient
pet
great
sourc
companionship
comfort
children
howev
sever
diseas
transmit
pet
immunosuppress
host
certain
anim
like
reptil
bird
rodent
exot
anim
immun
could
carri
unusu
human
pathogen
kept
pet
household
pho
hsct
patient
immunosuppress
patient
avoid
pet
zoo
due
risk
diseas
secondari
enter
pathogen
salmonella
campylobact
dog
cat
prefer
year
old
gener
consid
safe
pho
hsct
patient
routin
evalu
veterinarian
diseas
immun
kept
uptod
extrem
care
taken
maintain
hand
hygien
handl
pet
inform
regard
pet
therapi
avail
chap
studi
perform
adult
oncolog
patient
consist
shown
benefit
use
prophylact
antibiot
reduc
incid
bacteri
infect
levofloxacin
prophylaxi
adult
shown
reduc
incid
fever
bacteri
infect
hospit
rate
allcaus
mortal
base
upon
data
adult
idsa
guidelin
use
antimicrobi
agent
neutropen
patient
cancer
state
fluoroquinolon
prophylaxi
consid
highrisk
patient
prolong
sever
neutropenia
pediatr
studi
antibiot
prophylaxi
limit
pediatr
pilot
studi
use
ciprofloxacin
prophylaxi
pediatr
patient
receiv
delay
intensif
therapi
acut
lymphoblast
leukemia
show
reduct
hospit
intens
care
admiss
bacteremia
compar
control
anoth
studi
levofloxacin
prophylaxi
patient
reduc
odd
febril
neutropenia
possibl
bacteri
infect
confirm
bloodstream
infect
also
reduc
use
broadspectrum
antibiot
incid
c
difficil
infect
studi
howev
ciprofloxacin
prophylaxi
decreas
incid
overal
bacteremia
durat
fever
mortal
pediatr
acut
myelogen
leukemia
aml
patient
furthermor
increas
quinolon
resist
among
gramneg
organ
concern
recent
observ
nhsn
databas
pediatr
oncolog
patient
clabsi
addit
use
antimicrobi
prophylaxi
pho
could
increas
possibl
develop
mdro
invas
fungal
infect
drugrel
toxic
though
author
suggest
antibiot
prophylaxi
consid
children
undergo
induct
chemotherapi
current
insuffici
data
inform
definit
guidelin
antibiot
prophylaxi
prevent
bacteri
infect
pediatr
oncolog
patient
notabl
openlabel
random
clinic
trial
recent
conduct
levofloxacin
prophylaxi
vs
prophylaxi
children
aml
relaps
hsct
recipi
among
patient
aml
relaps
prophylaxi
associ
reduct
rate
bacteremia
numer
reduct
bacteremia
hsct
recipi
achiev
statist
signific
unclear
time
new
find
influenc
practic
futur
guidelin
infect
common
respiratori
gastrointestin
virus
result
signific
morbid
mortal
pho
hsct
patient
common
respiratori
virus
encount
includ
rhinoviru
coronaviru
adenoviru
rsv
parainfluenza
human
metapneumoviru
influenza
common
gastrointestin
virus
affect
healthi
immunocompromis
children
includ
noroviru
rotaviru
enter
adenovirus
enterovirus
among
other
infect
prevent
strategi
includ
educ
provid
patient
famili
hand
hygien
prevent
techniqu
avoid
ill
visitor
diseas
surveil
commun
hospit
vaccin
influenza
prompt
identif
test
treatment
possibl
respiratori
viral
ill
implement
routin
infect
control
prevent
polici
oncolog
ward
reduc
transmiss
common
respiratori
gastrointestin
virus
visitor
screen
sign
symptom
acut
viral
ill
restrict
visit
unit
contact
immunocompromis
host
chapter
outlin
infect
control
guidanc
hospit
visitor
greater
detail
immun
healthcar
worker
household
contact
need
special
consider
set
pho
hsct
patient
given
immunosuppress
statu
children
malign
andor
hsct
immun
closest
home
care
hospit
critic
import
prevent
infect
live
attenu
vaccin
contain
theoret
risk
transmit
immunocompromis
host
live
oral
polio
vaccin
longer
administ
unit
state
absolut
contraind
peopl
take
care
highrisk
popul
howev
data
suggest
measl
mump
rubella
mmr
varicella
zoster
herp
zoster
vaccin
safe
provid
healthcar
worker
household
contact
healthcar
personnel
develop
rash
cover
within
first
day
follow
receipt
varicella
vaccin
avoid
contact
immunocompromis
patient
rash
crust
avoid
potenti
risk
transmit
vaccin
strain
varicella
patient
infant
live
household
person
immunocompromis
includ
pho
hsct
patient
may
safe
immun
rotaviru
recommend
howev
immunocompromis
person
avoid
contact
infant
diapersstool
week
follow
vaccin
minim
risk
acquir
vaccin
strain
rotaviru
infect
inactiv
influenza
vaccin
prefer
personnel
take
care
immunocompromis
children
oppos
live
attenu
influenza
vaccin
vaccin
nonvir
pathogen
pneumococcu
pertussi
famili
member
anoth
import
method
minim
risk
seriou
infect
pho
patient
hospit
environ
design
minim
potenti
fungal
diseas
highestrisk
patient
high
effici
particul
air
hepa
filter
shown
reduc
nosocomi
infect
hsct
patient
cdc
recommend
hepa
filter
hsct
recipi
room
room
also
direct
airflow
posit
air
pressur
properli
ventil
air
chang
per
hour
avoid
carpet
upholsteri
also
recommend
sinc
outbreak
secondari
aspergillu
report
hospit
renov
construct
appropri
contain
place
strict
precaut
taken
prevent
exposur
patient
period
infect
control
prevent
depart
involv
risk
assess
plan
approv
construct
renov
project
healthcar
facil
includ
inpati
unit
clinic
infus
center
care
patient
cytotox
chemotherapi
radiat
therapi
use
treatment
malign
myelosuppress
result
variabl
durat
sever
neutropenia
addit
certain
malign
origin
bone
marrow
precursor
ie
leukemia
metastas
bone
marrow
eg
lymphoma
neuroblastoma
sarcoma
result
decreas
number
normal
blood
cell
precursor
consequ
neutropenia
henc
pediatr
cancer
hsct
patient
frequent
immunosuppress
risk
wide
rang
pathogen
febril
neutropenia
common
condit
phohsct
popul
regard
entiti
fever
defin
singl
temperatur
temperatur
two
occas
hour
apart
neutropenia
classifi
mild
absolut
neutrophil
count
anc
moder
anc
sever
anc
febril
neutropenia
also
known
fever
neutropenia
combin
two
event
patient
malign
hsct
common
complic
cancer
treatment
estim
patient
solid
tumor
patient
hematolog
malign
develop
fever
least
one
chemotherapi
cycl
associ
neutropenia
moreov
fever
may
indic
sever
underli
infect
sign
symptom
often
absent
minim
due
inadequ
inflammatori
respons
therefor
physician
must
particularli
awar
infect
risk
diagnost
method
antimicrobi
therapi
requir
manag
febril
neutropenia
cancer
patient
major
febril
episod
pathogen
identifi
clinic
document
infect
occur
case
patient
bacteremia
occur
episod
seen
set
prolong
andor
profound
neutropenia
anc
neutrophilsmm
hand
common
site
focal
infect
includ
gastrointestin
tract
lung
skin
past
five
decad
rate
antibiot
resist
epidemiolog
spectrum
bloodstream
pathogen
isol
febril
neutropen
patient
chang
substanti
select
pressur
broadspectrum
antimicrobi
therapi
andor
prophylaxi
earli
develop
cytotox
chemotherapi
gramneg
pathogen
predomin
febril
neutropenia
subsequ
gramposit
organ
becam
common
use
indwel
plastic
venou
cathet
becam
preval
allow
colon
subsequ
infect
gramposit
skin
flora
gramposit
bacteria
current
account
cultureposit
infect
pediatr
cancer
patient
importantli
recent
systemat
review
epidemiolog
antibiot
resist
pathogen
caus
bacteremia
cancer
patient
sinc
show
recent
shift
gramposit
gramneg
organ
main
caus
new
trend
determin
use
durat
antibiot
prophylaxi
import
factor
consid
incid
gramneg
bacteria
significantli
higher
group
receiv
antibiot
prophylaxi
use
antibiot
prophylaxi
howev
may
conceiv
select
resist
organ
increas
rate
antibiot
resist
gramneg
gramposit
bacteria
report
global
commun
well
cancer
popul
signific
concern
overal
common
blood
isol
set
febril
neutropenia
coagulaseneg
staphylococci
less
common
blood
isol
includ
enterobacteriacea
nonfer
gramneg
bacteria
pseudomona
aureu
streptococci
see
tabl
provid
review
local
data
institut
preval
blood
isol
antimicrobi
suscept
profil
manag
febril
neutropenia
continu
evolv
given
awar
intervent
previous
consid
standard
care
inpati
treatment
intraven
broadspectrum
antibiot
may
necessari
appropri
patient
becom
increasingli
import
identifi
patient
high
risk
infecti
complic
requir
aggress
manag
monitor
ie
inpati
set
intraven
antibiot
addit
clinician
may
abl
identifi
lowrisk
patient
popul
may
manag
less
aggress
costeffect
manner
ie
outpati
set
andor
oral
antibiot
order
address
issu
algorithm
approach
neutropen
fever
infect
prophylaxi
diagnosi
treatment
develop
well
establish
stratif
patient
determin
risk
complic
sever
infect
undertaken
present
fever
determin
type
empir
antibiot
therapi
oral
vs
intraven
venu
treatment
inpati
vs
outpati
durat
antibiot
therapi
gener
risk
seriou
infect
directli
relat
degre
durat
neutropenia
pediatr
patient
mild
anc
brief
period
neutropenia
day
less
like
infecti
complic
dutta
r
flore
moder
sever
neutropenia
anc
last
day
similarli
risk
bacteremia
septicemia
increas
dramat
anc
infecti
complic
common
sever
prolong
neutropenia
includ
bacteremia
pneumon
cellul
abscess
format
import
consid
individu
patient
risk
incorpor
latest
recommend
manag
neutropen
fever
children
cancer
hsct
patient
gener
stratifi
either
high
low
risk
follow
highrisk
patient
anticip
prolong
day
durat
profound
neutropenia
anc
cellsmm
follow
cytotox
chemotherapi
andor
signific
medic
comorbid
condit
includ
hypotens
pneumonia
newonset
abdomin
pain
neurolog
chang
lowrisk
patient
anticip
brief
day
durat
neutropen
period
comorbid
addit
risk
classif
may
base
multin
associ
support
care
cancer
mascc
score
tabl
mascc
risk
score
recommend
threshold
definit
low
risk
patient
develop
seriou
medic
complic
compar
score
howev
mascc
score
develop
valid
adult
valid
pediatr
popul
consensu
field
patient
consid
high
risk
mascc
clinic
criteria
treat
inpati
empir
iv
antibiot
therapi
care
select
lowrisk
patient
may
candid
oral
andor
outpati
empir
antibiot
therapi
tabl
summar
recommend
manag
febril
neutropenia
base
recommend
idsa
intern
pediatr
fever
neutropenia
guidelin
panel
importantli
neutropen
febril
patient
obviou
sourc
infect
clinic
exam
manag
tailor
sourc
note
adequ
antibiot
stewardship
utmost
import
treatment
neutropen
patient
order
decreas
incid
antibioticrel
advers
drug
event
preval
antibiot
resist
decreas
treatment
cost
blood
cultur
must
close
monitor
microorgan
identifi
appropri
plan
antibiot
deescal
andor
treatment
durat
promptli
institut
invas
fungal
diseas
ifd
one
lead
caus
morbid
mortal
pho
hsct
patient
present
mani
diagnost
therapeut
challeng
one
princip
risk
factor
contribut
develop
ifd
relat
patient
oncolog
diagnosi
patient
aml
highrisk
relaps
recipi
allogen
hsct
chronic
sever
acut
graftversushost
diseas
gvhd
highest
risk
ifd
often
combin
risk
factor
present
patient
may
includ
prolong
neutropenia
highdos
corticosteroid
use
immunosuppress
therapi
parenter
nutrit
presenc
cvc
preced
antibiot
therapi
presenc
bacteri
coinfect
oral
mucos
admiss
intens
care
unit
highest
risk
ifd
period
profound
neutropenia
hsct
recipi
occur
first
day
posttranspl
neutrophil
engraft
pho
patient
highest
risk
period
induct
chemotherapi
highrisk
patient
use
monotherapi
antipseudomon
fourth
gener
cephalosporin
carbapenem
empir
therapi
pediatr
highrisk
fn
depend
local
preval
multidrugresist
gramneg
rod
strong
recommend
highqual
evid
reserv
addit
second
gramneg
agent
glycopeptid
patient
clinic
unstabl
resist
infect
suspect
center
high
rate
resist
pathogen
era
grow
prophylact
antifung
use
children
receiv
moldact
agent
shown
higher
risk
nonaspergillu
speci
fungal
infect
voriconazol
prophylaxi
adult
shown
independ
risk
factor
mucormycos
likewis
breakthrough
trichosporonosi
also
report
patient
receiv
micafungin
prophylaxi
phenomena
like
part
relat
select
fungi
reduc
intrins
suscept
prophylact
agent
common
ifd
invas
aspergillosi
ia
invas
candidiasi
ic
recent
upward
trend
seen
nonaspergillu
mold
infect
among
aspergillu
speci
fumigatu
common
follow
flavu
anig
among
nonaspergillu
mold
mucormycos
rhizopu
mucor
absidia
frequent
report
follow
number
speci
eg
fusarium
scedosporium
curvularia
exserohilum
etc
among
ic
c
albican
singl
common
candida
speci
nonalbican
candida
speci
especi
c
parapsilosi
c
tropicali
increasingli
report
among
popul
ifd
suspect
patient
fever
neutropenia
last
day
without
identifi
caus
ic
present
septic
shock
may
nonspecif
find
fever
cough
nauseavomit
abdomin
pain
cutan
lesion
depend
site
involv
children
common
site
ic
lung
liver
spleen
dissemin
occur
organ
includ
heart
eye
brain
dissemin
diseas
independ
risk
factor
death
children
ic
primari
site
ia
lung
skin
sinus
clinic
present
fungal
rhinosinus
may
includ
fever
rhinorrhea
nasal
congest
facial
pain
mani
case
howev
may
present
symptom
may
diagnos
base
imag
perform
persist
febril
patient
profound
prolong
neutropenia
cutan
lesion
present
macul
papul
nodular
ulcer
lesion
without
surround
erythema
tender
clinic
present
secondari
mold
fusarium
scedosporium
indistinguish
ia
mucormycos
deserv
special
mention
sinc
dissemin
death
higher
due
ifd
caus
speci
compar
ia
earli
recognit
prompt
treatment
ifd
crucial
optim
manag
diagnost
test
includ
blood
cultur
though
often
low
sensit
cultur
appropri
steril
site
urin
csf
diagnost
biopsi
involv
site
cultur
histopatholog
fungal
biomark
use
screen
test
highrisk
period
adjunct
diagnost
test
patient
suspect
ifd
especi
period
prolong
fever
neutropenia
galactomannan
gm
cell
wall
compon
releas
aspergillu
speci
detect
blood
bronchoalveolar
lavag
fluid
cerebrospin
fluid
cutoff
valu
gm
optic
index
blood
bronchoalveolar
lavag
fluid
level
consid
posit
test
though
optimum
cutoff
valu
well
defin
children
invas
fungal
diseas
due
fungi
aspergillu
speci
may
neg
galactomannan
test
cell
wall
compon
found
mani
speci
fungi
elev
serum
assay
caus
ic
ia
mold
optimum
cutoff
valu
posit
test
unknown
children
pgml
use
studi
gm
assay
variabl
sensit
specif
among
children
interpret
caution
sensit
gm
report
rang
children
malign
ia
contrast
assay
high
sensit
ifd
suffer
poor
specif
falseposit
due
system
bacteri
viral
coinfect
receipt
antibiot
piperacillintazobactam
amoxicillinclavulan
hemodialysi
receipt
albumin
intraven
immunoglobulin
materi
contain
glucan
oral
mucos
gi
mucos
breakdown
pcrbase
fungal
diagnost
test
investig
low
sensit
specif
gm
monitor
twice
weekli
suggest
evalu
treatment
respons
confirmedprob
diseas
screen
tool
patient
high
risk
ifd
pho
hsct
patient
febril
neutropenia
persist
beyond
day
andor
suspect
ifd
undergo
comput
tomographi
chest
abdomen
pelvi
area
indic
common
find
imag
suggest
ifd
pulmonari
nodul
especi
halo
sign
air
crescent
sign
cavit
hepatosplen
renal
nodul
also
rais
suspicion
ifd
studi
consid
includ
echocardiogram
dilat
retin
examin
especi
patient
dissemin
candidiasi
symptom
sinus
new
lesion
palat
present
prompt
nasal
endoscop
examin
ct
sinus
warrant
three
main
class
antifung
use
patient
ifd
polyen
includ
amphotericin
b
amb
lipid
formul
liposom
amb
commonli
use
pho
hsct
patient
triazol
fluconazol
itraconazol
voriconazol
posaconazol
echinocandin
caspofungin
micafungin
anidulafungin
antifung
prophylaxi
consid
patient
high
risk
ifd
includ
hsct
recipi
undergo
intens
remissioninduct
therapi
salvageinduct
therapi
high
incid
ifd
report
children
aml
newli
diagnos
relaps
patient
relaps
patient
may
consid
candid
prophylaxi
among
hsct
recipi
unrel
donor
partial
match
donor
higher
risk
ifd
recent
studi
show
children
aml
receiv
antifung
prophylaxi
reduc
rate
induct
mortal
resourc
util
compar
receiv
prophylaxi
posaconazol
found
superior
fluconazol
itraconazol
reduc
incid
ifd
children
echinocandin
shown
effect
ifd
prophylaxi
triazol
especi
hsct
recipi
less
advers
effect
altern
option
prophylaxi
idsa
european
confer
infect
leukemia
recommend
use
posaconazol
voriconazol
micafungin
prolong
neutropenia
prevent
ifd
posaconazol
recommend
prophylaxi
patient
gvhd
high
risk
ia
variabl
absorpt
oral
azol
children
taken
consider
choos
oral
antifung
patient
prolong
fever
neutropenia
without
altern
explan
consider
must
given
possibl
activ
fungal
infect
empir
antifung
therapi
consid
neutropen
patient
persist
recurr
fever
day
antibiot
therapi
whose
overal
durat
neutropenia
expect
day
lowrisk
patient
routin
use
empir
antifung
recommend
liposom
amphotericin
b
echinocandin
fungicid
firstlin
therapi
empir
antifung
treatment
insuffici
data
provid
specif
guidanc
patient
concern
new
fungal
infect
alreadi
receiv
moldact
ie
antiaspergillu
prophylaxi
howev
expert
suggest
switch
differ
moldact
antifung
surgic
debrid
fungal
lesion
abscess
prompt
remov
cvc
event
fungemia
crucial
reduc
progress
ifd
therapeut
drug
monitor
tdm
perform
patient
receiv
voriconazol
itraconazol
posaconazol
extrem
variabl
triazol
serum
level
among
pediatr
patient
owe
divers
bioavail
popul
voriconazol
tdm
serum
trough
level
mcgdl
consid
safe
effect
prevent
breakthrough
ifd
children
posaconazol
trough
level
mgl
shown
effect
due
increas
toxic
associ
vinca
alkaloid
high
dose
cyclophosphamid
anthracyclin
azol
coadminist
agent
antifung
agent
commonli
use
children
pho
hsct
indic
note
tabl
although
combin
antifung
well
studi
children
use
frequent
popul
pediatr
data
variabl
regard
benefit
combin
antifung
therapi
overal
report
increas
advers
event
risk
system
toxic
must
therefor
taken
account
consid
use
antifung
combin
combin
therapi
could
consid
patient
refractori
diseas
salvag
therapi
granulocyt
transfus
profound
persist
neutropenia
adjunct
cytokin
eg
granulocyt
colonystimul
factor
gcsf
reduct
immunosuppress
taper
steroid
recommend
adjunct
antifung
agent
treatment
ifd
summari
children
adolesc
malign
addit
risk
factor
healthcareassoci
infect
meticul
attent
person
oral
hygien
diet
environment
safeti
appropri
immun
practic
highrisk
popul
use
antimicrobi
prophylaxi
consid
period
sever
neutropenia
prevent
bacteri
fungal
infect
necessari
prompt
diagnosi
manag
strategi
prevent
infecti
complic
key
prevent
morbid
mortal
immunocompromis
host
